宫颈癌病人切除修复交叉互补基因1基因多态性与铂类超敏反应关系  

Relationship between excision repair cross-complementation group 1 gene polymorphism and platinum hypersensitivity in patients with cervical cancer

作　　者：侯丽娟[1] 王文文 翟建军[1] 孙燕[1] HOU Lijuan;WANG Wenwen;ZHAI Jianjun;SUN Yan(Department of Obstetrics and Gynecology,Beijing Tongren Hospital,Capital Medical University,Beijing 100176,China)

机构地区：[1]首都医科大学附属北京同仁医院妇产科,北京100176

出　　处：《安徽医药》2022年第3期549-553,共5页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探究宫颈癌病人切除修复交叉互补基因1(excisionrepaircrosscomplement 1,ERCC1)基因多态性与铂类超敏反应关系及其危险因素。方法选取2012年1月至2017年9月首都医科大学附属北京同仁医院收治的103例宫颈癌病人作为研究对象,均接受以铂类为基础的联合化疗,21 d为1个化疗周期,化疗1~2周期后,统计化疗效果,以此分为敏感组(n=71)和耐药组(n=32),统计两组ERCC1 rs11615位点基因型分布及logistic回归分析宫颈癌铂类化疗敏感性与临床病理参数的关系,比较不同ERCC1 rs11615位点基因型分布中位无进展生存期(PFS)。结果(1)敏感组ERCC1 rs11615位点CT基因型(64.79%)高于耐药组(18.75%),且携带ERCC1 rs11615位点CT基因型的宫颈癌病人化疗耐药的风险低于CC基因型(P<0.05);(2)临床分期Ⅳ期、ERCC1 rs11615 CC基因型、有淋巴结转移、深间质浸润、低分化程度与宫颈癌铂类化疗敏感性密切相关(P<0.05);(3)临床分期Ⅳ期(OR=3.95)、ERCC1 rs11615 CC基因型(OR=4.31)、有淋巴结转移(OR=3.98)、深间质浸润(OR=6.82)、低分化程度(OR=4.85)是影响宫颈癌铂类化疗敏感性危险因素(P<0.05);(4)log-rank分析显示,ERCC1 rs11615位点CC基因型的中位PFS(9.8个月)和CT基因性(10.9个月)比较,差异无统计学意义(P>0.05)。结论宫颈癌病人铂类超敏反应与ERCC1 rs11615基因型、临床分期、淋巴结转移、分化程度等因素有关,建议临床重点观察上述指标,为宫颈癌铂类化疗超敏反应鉴别诊断提供指导依据。Objective To explore the relationship between excision repair cross-complementation group 1(ERCC1)gene polymor⁃phisms and platinum hypersensitivity reaction and its risk factors in patients with cervical cancer.Methods A total of 103 cervical cancer patients admitted to Beijing Tongren Hospital,CMU from January 2012-September 2017 were selected as the research subjects.All patients received platinum-based combination chemotherapy in a 21-day cycle.After one to two cycles of chemotherapy,the effects of chemotherapy were calculated,and the patients were divided into a sensitive group(n=71)and a resistant group(n=32).The geno⁃type distribution of ERCC1 rs11615 in the two groups was calculated,the relationship between platinum chemotherapy sensitivity and the clinical pathological parameters of cervical cancer was analyzed by logistic regression,and the median progression-free survival(PFS)of ERCC1 rs11615 locus genotype distribution was compared.Results(1)The CT genotype of the ERCC1 rs11615 locus in the sensitive group was 64.79%higher than that in the drug-resistant group(18.75%),and the risk of chemotherapy resistance in cervical cancer patients with the CT genotype of the ERCC1 rs11615 loci was lower than that in the CC genotype(P<0.05).(2)Clinical stageⅣ,ERCC1 rs11615 CC genotype,lymph node metastasis,deep interstitial invasion,and low degree of differentiation were closely related to the sensitivity of platinum-based chemotherapy to cervical cancer(P<0.05).(3)Clinical stageⅣ(OR=3.95),ERCC1 rs11615 CC genotype(OR=4.31),lymph node metastasis(OR=3.98),deep interstitial invasion(OR=6.82),and low degree of differentiation(OR=4.85)are risk factors affecting platinum chemotherapy sensitivity of cervical cancer(P<0.05).(4)Log-rank analysis showed that there was no significant difference in the median PFS(9.8 months)and CT genotype(10.9 months)of the CC genotype at ERCC1 rs11615(P>0.05).Conclusions Platinum hypersensitivity in cervical cancer patients is related to the ERCC1 rs11615 genotype,clinical stage,lymp

关 键 词：宫颈肿瘤 切除修复交叉互补基因1基因多态性 铂类超敏反应 CT基因型 CC基因型 淋巴结转移 间质浸润 

分 类 号：R737.33[医药卫生—肿瘤]